Skip to main content
. Author manuscript; available in PMC: 2020 Jan 9.
Published in final edited form as: AIDS Care. 2019 Jan 9;30(SUP4):21–33. doi: 10.1080/09540121.2018.1503224

Table 3.

Outcomes by intervention condition among those starting ART in past 3 months

Battle Viro Intervention Control Effect Size Difference
(didc)c
Pretest Post a Pretest Posta
d b d b F d p
Log Viral Load (M (SD)) 3.63 (1.11) 0.93 (1.63) −2.74 3.94 (0.90) 1.53 (2.49) −0.53 −2.21 4.33 0.04
Wisepill 7-day Adherence
(M (SD))
0.70 (0.35) 0.71 (0.32) 0.03 0.86 (0.17) 0.48 (0.44) −1.12 1.15 3.90 0.05
Self-Report 7-day Adherence
(M (SD))
0.96 (0.09) 0.88 (0.31) −0.35 0.97 (0.06) 0.91 (0.30) −0.27 −0.08 0.05 0.82
HIV Knowledge (M (SD)) 2.27 (0.79) 2.91 (1.45) 0.55 2.90 (0.94) 2.55 (1.13) −0.35 0.90 0.52 0.47
ART Treatment Knowledge
(M (SD))
11.82 (3.46) 13.18 (1.94) 0.47 12.45 (1.81) 11.63 (4.23) −0.25 0.72 0.42 0.52
Motivation for ART
(M (SD))
13.18 (3.22) 12.00 (4.12) −0.32 10.70 (4.19) 12.20 (3.52) 0.39 −0.71 0.39 0.53
Self-Efficacy for ART Skills
(M (SD))
19.18 (3.71) 19.09 (5.65) −0.02 18.36 (5.51) 19.36 (3.64) 0.21 −0.23 0.56 0.46
Social Support
(M (SD))
27.64 (3.32) 27.64 (5.18) 0 25.45 (2.94) 25.00 (4.02) −0.13 0.13 0.03 0.87
a

: 16-weeks post-baseline

b

: Cohen’s d

c

: Cohen’s d effect size difference (Battle Viro - Control)

d

: ANCOVA interaction statistic between intervention condition and newly starting ARV in past 3 months in entire sample, controlling for baseline